The effect of Bi promoter on vanadium phosphate catalysts synthesized via sesquihydrate route

A series of 1%, 3% and 5% Bi-doped vanadyl pyrophosphate catalysts were prepared via sesquihydrate route (VPOs method). These catalysts were denoted as VPOs-Bi1%, VPOs-Bi3% and VPOs-Bi5%. Bulk and Bi-promoted vanadyl pyrophosphate catalysts prepared via sesquihydrate route exhibited a well-crystallized (VO)2P2O7 phase. Two V5+ phases, i.e. β-VOPO4 and αII-VOPO4 were observed in all Bi-promoted VPO catalysts, which led to an increase in the specific surface area and average oxidation state of vanadium. Bi-promoted VPO catalysts showed six to nine times higher amounts of oxygen evolved than the bulk VPO catalyst in oxygen TPD and a significant shift in the reduction peaks to lower temperatures. Catalytic tests revealed that both activity and selectivity to maleic anhydride increased with the presence of bismuth promoter

Preparation of Metal Organic Framework (MOF) Derived Bimetallic Catalyst for Dry Reforming of Methane

In the past decade, efforts have been focused on development of catalyst to show high activity for dry reforming of methane (DRM). The development of catalyst has been crucial to be carried out as this may significantly reduce the concentration of most common greenhouse gases, namely methane (CH4) and carbon dioxide (CO2) in the atmosphere. In present work, a series of varying molar ratio of Ni:Ce metal organic framework (MOF) derived catalysts were grown on alumina in one step. The synthesis steps were in accordance to reported solvothermal method for the syntheses of NH2-MIL-88B with slight modification. This was followed by reduction at 500°C in hydrogen environment for 1 h. The physical and chemical properties of the catalysts were probed by powder XRD, BET surface area analysis, EDX, ICP, CO2-TPD and H2-TPR. XRD showed that diffraction patterns were in agreement with the diffraction pattern of MOF synthesized in previous work, thus confirmed the successful formation of the MOF structure. The variation in the molar ratio of Ni:Ce did not show significant difference in the diffraction pattern of the MOF-derived catalysts. For reduction phase, sharp diffraction peaks were detected at 2? = 44.5°, 51.85°, and 76.37°, which can be indexed to (1 1 1), (2 0 0) and (2 2 0) planes of face-centered cubic (FCC) metallic Ni, respectively. The addition of Ce promoted smaller particle size of Ni, ranging from 4.6 nm to 6.88 nm. The presence of CeO2 was observed at 2? = 28.6°, 33.0°, and 56.4°. Elemental distribution was compared between EDX and ICP-OES. ICP-OES and EDX analyses indicated that weight percent of bimetallic metal of Ni and Ce was consistent, in which the amount of respective metal obeyed the ratio trend of the metal precursors added during the MOF synthesis. This suggested the homogeneity of the catalyst, even though EDX showed relatively higher weight percent than ICP-OES. The catalytic performance of catalysts showed that 1Ni1Ce exhibited better conversion of CH4 and CO2, with 63.5% and 86.8% respectively at 800oC, and the conversion tend to increase at a higher temperature. The results were convincing for the design of a performing catalyst for DRM process

Critical Review of the Various Reaction Mechanisms for Glycerol Etherification

This review provides in-depth coverage of numerous mechanisms available for the etherification process of glycerol, including alcohol solvent, olefin solvent and solvent-free routes along with products that are formed at various stages of the reaction. Mono tert-butyl glycerol ether (MTBG), di tert-butyl glycerol ether (DTBG), and tri tert-butyl glycerol ether (TTBG) are the three general ether compounds obtained through tert-butyl alcohol (TBA) etherification. Glycerol etherification with n-butanol results in the formation of glycerol ether products that are linked to the substituted butyl groups. These products include two mono-butyl glycerol ethers, two di-butyl glycerol ethers and a tri-butyl glycerol ether. Two mono-benzyl glycerol ether isomers, two di-benzyl glycerol ether isomers and tri-benzyl glycerol ether are the most reported results when benzyl alcohol is used as a solvent in the etherification reaction. The etherification of glycerol with 1-butene involves a series of equilibrium reactions to produce mono-ethers, di-ethers, and tri-ethers, whereas the etherification of glycerol with isobutene is carried out via tert-butylation of glycerol, yielding similar glycerol ether products when TBA is used as a solvent. As the by-product may be easily removed, the solvent-free glycerol etherification approach may have several advantages over the other conventional methods. Therefore, further studies on base-catalyzed glycerol etherification that employs a solvent-free reaction route may reveal a method for improving the conversion, selectivity, and yield of reaction products. This review study is crucial in improving knowledge of numerous mechanisms and how they relate to the effectiveness of the product’s catalytic process

Carbon capture from low CO2 concentration stream through ternary alkali metal nitrates promotion of MgO sorbents at intermediate temperature and low space velocity

Many MgO sorbents exhibit high CO2 uptake in the presence of high concentration CO2 and aided by high space velocity, which unfortunately leads to low CO2 capture efficiency from the gas stream. This study investigates the effect of Li/Na/K ratio on sorption performance in dilute CO2 streams (15% CO2) using alkali metal nitrates-promoted MgO sorbents at a low space velocity of 20 ml/g·min in fixed bed reactor. Study shows that the ratio of Li/Na/K in ternary alkali nitrate salt mixture significantly affects the induction periods for the second phase CO2 sorption, which is a key contributor to high CO2 uptake. High LiNO3 content in ternary mixture leads to long induction period, and therefore lower CO2 capacity during the 4 h period. Conversely, high ratios of NaNO3 and KNO3 leads to shorter induction periods. Among the samples, MgO with 9 mol% (Li0.18Na0.52K0.3) exhibits the highest CO2 sorption capacity of 5.56 mmol/g at 240°C in 4 h (20.6% CO2 capture efficiency) and 3.18 mmol/g after 5 cycles (10.8% CO2 capture efficiency). Comparative studies show that optimal temperatures for CO2 sorption are higher when using pure CO2 (280 to 320°C) than when using 15% CO2 (240°C) due to the thermodynamic equilibrium. CO2-TPD results indicate that CO2 desorption proceeds in two phases similar to CO2 sorption, and the presence of alkali salt in MgO also promotes the decomposition of bulk carbonate to CO2. It is shown that molten salt migration and agglomeration of MgO particles are likely the factors that lead to decline in CO2 uptake over the sorption-desorption cycles

Paediatric COVID-19 mortality: a database analysis of the impact of health resource disparity

Background The impact of the COVID-19 pandemic on paediatric populations varied between high-income countries (HICs) versus low-income to middle-income countries (LMICs). We sought to investigate differences in paediatric clinical outcomes and identify factors contributing to disparity between countries.Methods The International Severe Acute Respiratory and Emerging Infections Consortium (ISARIC) COVID-19 database was queried to include children under 19 years of age admitted to hospital from January 2020 to April 2021 with suspected or confirmed COVID-19 diagnosis. Univariate and multivariable analysis of contributing factors for mortality were assessed by country group (HICs vs LMICs) as defined by the World Bank criteria.Results A total of 12 860 children (3819 from 21 HICs and 9041 from 15 LMICs) participated in this study. Of these, 8961 were laboratory-confirmed and 3899 suspected COVID-19 cases. About 52% of LMICs children were black, and more than 40% were infants and adolescent. Overall in-hospital mortality rate (95% CI) was 3.3% [=(3.0% to 3.6%), higher in LMICs than HICs (4.0% (3.6% to 4.4%) and 1.7% (1.3% to 2.1%), respectively). There were significant differences between country income groups in intervention profile, with higher use of antibiotics, antivirals, corticosteroids, prone positioning, high flow nasal cannula, non-invasive and invasive mechanical ventilation in HICs. Out of the 439 mechanically ventilated children, mortality occurred in 106 (24.1%) subjects, which was higher in LMICs than HICs (89 (43.6%) vs 17 (7.2%) respectively). Pre-existing infectious comorbidities (tuberculosis and HIV) and some complications (bacterial pneumonia, acute respiratory distress syndrome and myocarditis) were significantly higher in LMICs compared with HICs. On multivariable analysis, LMIC as country income group was associated with increased risk of mortality (adjusted HR 4.73 (3.16 to 7.10)).Conclusion Mortality and morbidities were higher in LMICs than HICs, and it may be attributable to differences in patient demographics, complications and access to supportive and treatment modalities

Empagliflozin in Patients with Chronic Kidney Disease

Background The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of such patients. Methods We enrolled patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m(2) of body-surface area, or who had an eGFR of at least 45 but less than 90 ml per minute per 1.73 m(2) with a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 200. Patients were randomly assigned to receive empagliflozin (10 mg once daily) or matching placebo. The primary outcome was a composite of progression of kidney disease (defined as end-stage kidney disease, a sustained decrease in eGFR to < 10 ml per minute per 1.73 m(2), a sustained decrease in eGFR of & GE;40% from baseline, or death from renal causes) or death from cardiovascular causes. Results A total of 6609 patients underwent randomization. During a median of 2.0 years of follow-up, progression of kidney disease or death from cardiovascular causes occurred in 432 of 3304 patients (13.1%) in the empagliflozin group and in 558 of 3305 patients (16.9%) in the placebo group (hazard ratio, 0.72; 95% confidence interval [CI], 0.64 to 0.82; P < 0.001). Results were consistent among patients with or without diabetes and across subgroups defined according to eGFR ranges. The rate of hospitalization from any cause was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.86; 95% CI, 0.78 to 0.95; P=0.003), but there were no significant between-group differences with respect to the composite outcome of hospitalization for heart failure or death from cardiovascular causes (which occurred in 4.0% in the empagliflozin group and 4.6% in the placebo group) or death from any cause (in 4.5% and 5.1%, respectively). The rates of serious adverse events were similar in the two groups. Conclusions Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo

Association of Country Income Level With the Characteristics and Outcomes of Critically Ill Patients Hospitalized With Acute Kidney Injury and COVID-19

Introduction: Acute kidney injury (AKI) has been identified as one of the most common and significant problems in hospitalized patients with COVID-19. However, studies examining the relationship between COVID-19 and AKI in low- and low-middle income countries (LLMIC) are lacking. Given that AKI is known to carry a higher mortality rate in these countries, it is important to understand differences in this population. Methods: This prospective, observational study examines the AKI incidence and characteristics of 32,210 patients with COVID-19 from 49 countries across all income levels who were admitted to an intensive care unit during their hospital stay. Results: Among patients with COVID-19 admitted to the intensive care unit, AKI incidence was highest in patients in LLMIC, followed by patients in upper-middle income countries (UMIC) and high-income countries (HIC) (53%, 38%, and 30%, respectively), whereas dialysis rates were lowest among patients with AKI from LLMIC and highest among those from HIC (27% vs. 45%). Patients with AKI in LLMIC had the largest proportion of community-acquired AKI (CA-AKI) and highest rate of in-hospital death (79% vs. 54% in HIC and 66% in UMIC). The association between AKI, being from LLMIC and in-hospital death persisted even after adjusting for disease severity. Conclusions: AKI is a particularly devastating complication of COVID-19 among patients from poorer nations where the gaps in accessibility and quality of healthcare delivery have a major impact on patient outcomes